Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6569427

Title:Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
Inventors:Boyse, Edward A.; Tucson, AZ, USA
Broxmeyer, Hal E.; Indianapolis, IN, USA
Douglas, Gordon W.; New York, NY, USA
Summary:Described herein are methods of providing hematopoietic reconstitution via introduction into the patient of a composition having a cryoprotective agent such as dimethyl sulfoxide and human neonatal or fetal hematopoietic stem or progenitor cells. The invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. Therapeutic applications in immune reconstitution are included, such as for the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. Various embodiments of the invention include fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence which can be used for hematopoietic reconstitution in gene therapy. Further disclosed are methods by which neonatal or fetal blood cells that have been cryopreserved and thawed may be used in autologous reconstitution.
Abstract:The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6569427
Application Number:US1995000442277
Date Filed:16/05/2995
Date Published:27/05/2003
Assignee:PharmaStem Therapeutics, Inc., Del Mar, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021